Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(1):26-32; doi:10.1093/jnci/94.1.26
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Esteller, M.
Right arrow Articles by Herman, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esteller, M.
Right arrow Articles by Herman, J. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 1, 26-32, January 2, 2002
© 2002 Oxford University Press


ARTICLE

Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma

Manel Esteller, Gianluca Gaidano, Steven N. Goodman, Vittorina Zagonel, Daniela Capello, Barbara Botto, Davide Rossi, Annunziata Gloghini, Umberto Vitolo, Antonino Carbone, Stephen B. Baylin, James G. Herman

Affiliations of authors: M. Esteller, Division of Cancer Biology, The Johns Hopkins Oncology Center, Baltimore, MD, and Cancer Epigenetics Laboratory, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, Majadahonda, Spain; G. Gaidano, D. Capello, D. Rossi, The Center for the Study and Treatment of Blood Disorders, Division of Internal Medicine, Department of Medical Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; S. N. Goodman (Division of Biostatistics), S. B. Baylin, J. G. Herman (Division of Cancer Biology), The Johns Hopkins Oncology Center; V. Zagonel (Division of Medical Oncology B), A. Gloghini, A. Carbone (Division of Pathology), Centro di Riferimento Oncologico—Istituto Nazionale Tumori, Aviano, Italy; B. Botto, U. Vitolo, Division of Hematology, A.O. San Giovanni Battista della Città di Torino, Italy.

Correspondence to: James G. Herman, M.D., The Johns Hopkins Oncology Center, 1650 Orleans, Baltimore, MD 21231 (e-mail: hermanji{at}jhmi.edu).

Background: The gene encoding the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) is transcriptionally silenced by promoter hypermethylation in several human cancers, including diffuse large B-cell lymphoma (B-DLCL). MGMT promoter hypermethylation is a favorable prognostic marker in patients with brain tumors treated with alkylating agents. Methods: In a retrospective cohort study, we used methylation-specific polymerase chain reaction to analyze the MGMT promoter methylation status in tumor DNA of B-DLCL patients receiving cyclophosphamide as part of multidrug regimens. Molecular data were compared with patient response with the use of Student's t test. Disease-free survival and overall survival were estimated by the Kaplan–Meier method and compared with the use of the log-rank test. Multivariable survival analyses were performed with the Cox proportional hazards model. All statistical tests were two-sided. Results: Thirty (36%) of 84 B-DLCL patients showed MGMT promoter hypermethylation in their lymphomas. The presence of MGMT methylation was associated with a statistically significant increase in overall survival (hazard ratio for time to death for nonmethylation versus methylation = 2.8; 95% confidence interval (CI) = 1.2 to 7.5; P = .01) and progression-free survival (hazard ratio for time to progression for nonmethylation versus methylation = 2.6; 95% CI = 1.3 to 5.8; P = .02). MGMT promoter hypermethylation was both independent of and stronger than established prognostic factors, such as age, disease stage, serum lactic dehydrogenase level, and performance status. Conclusion: MGMT promoter hypermethylation appears to be a useful marker for predicting survival in patients with B-DLCL treated with multidrug regimens including cyclophosphamide.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi
Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas
Ann. Onc., October 1, 2008; 19(10): 1774 - 1786.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
R. Nagasubramanian, R. J. Hansen, S. M. Delaney, M. M. Cherian, L. D. Samson, S. C. Kogan, and M. E. Dolan
Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure
Mutagenesis, September 1, 2008; 23(5): 341 - 346.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
I. Vlassenbroeck, S. Califice, A.-C. Diserens, E. Migliavacca, J. Straub, I. Di Stefano, F. Moreau, M.-F. Hamou, I. Renard, M. Delorenzi, et al.
Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
J. Mol. Diagn., July 1, 2008; 10(4): 332 - 337.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Esteller
Epigenetics in Cancer
N. Engl. J. Med., March 13, 2008; 358(11): 1148 - 1159.
[Full Text] [PDF]


Home page
JCOHome page
T. M. Horton, P. A. Thompson, S. L. Berg, P. C. Adamson, A. M. Ingle, M. E. Dolan, S. M. Delaney, M. Hedge, H. L. Weiss, M.-F. Wu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study
J. Clin. Oncol., November 1, 2007; 25(31): 4922 - 4928.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Martone, A. Gillio-Tos, L. De Marco, V. Fiano, M. Maule, A. Cavalot, M. Garzaro, F. Merletti, and G. Cortesina
Association Between Hypermethylated Tumor and Paired Surgical Margins in Head and Neck Squamous Cell Carcinomas
Clin. Cancer Res., September 1, 2007; 13(17): 5089 - 5094.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. Martinez, F. Setien, C. Voelter, S. Casado, M. P. Quesada, G. Schackert, and M. Esteller
CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme
Carcinogenesis, June 1, 2007; 28(6): 1264 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
T. K. Wojdacz and A. Dobrovic
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation
Nucleic Acids Res., March 19, 2007; 35(6): e41 - e41.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. A. Hill, S. S. Wang, J. R. Cerhan, S. Davis, W. Cozen, R. K. Severson, P. Hartge, S. Wacholder, M. Yeager, S. J. Chanock, et al.
Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes
Blood, November 1, 2006; 108(9): 3161 - 3167.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Teodoridis, J. Hall, S. Marsh, H. D. Kannall, C. Smyth, J. Curto, N. Siddiqui, H. Gabra, H. L. McLeod, G. Strathdee, et al.
CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer
Cancer Res., October 1, 2005; 65(19): 8961 - 8967.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Agrelo, F. Setien, J. Espada, M. J. Artiga, M. Rodriguez, A. Perez-Rosado, A. Sanchez-Aguilera, M. F. Fraga, M. A. Piris, and M. Esteller
Inactivation of the Lamin A/C Gene by CpG Island Promoter Hypermethylation in Hematologic Malignancies, and Its Association With Poor Survival in Nodal Diffuse Large B-Cell Lymphoma
J. Clin. Oncol., June 10, 2005; 23(17): 3940 - 3947.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. van Doorn, W. H. Zoutman, R. Dijkman, R. X. de Menezes, S. Commandeur, A. A. Mulder, P. A. van der Velden, M. H. Vermeer, R. Willemze, P. S. Yan, et al.
Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73
J. Clin. Oncol., June 10, 2005; 23(17): 3886 - 3896.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
Y. Koga, Y. Kitajima, A. Miyoshi, K. Sato, K. Kitahara, H. Soejima, and K. Miyazaki
Tumor Progression Through Epigenetic Gene Silencing of O6-Methylguanine-DNA Methyltransferase in Human Biliary Tract Cancers
Ann. Surg. Oncol., May 1, 2005; 12(5): 354 - 363.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. R.J. Kohonen-Corish, J. J. Daniel, C. Chan, B. P.C. Lin, S. Y. Kwun, O. F. Dent, V. S. Dhillon, R. J.A. Trent, P. H. Chapuis, and E. L. Bokey
Low Microsatellite Instability Is Associated With Poor Prognosis in Stage C Colon Cancer
J. Clin. Oncol., April 1, 2005; 23(10): 2318 - 2324.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. F. Paz, R. Yaya-Tur, I. Rojas-Marcos, G. Reynes, M. Pollan, L. Aguirre-Cruz, J. L. Garcia-Lopez, J. Piquer, M.-J. Safont, C. Balana, et al.
CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas
Clin. Cancer Res., August 1, 2004; 10(15): 4933 - 4938.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Zuo, L. Ai, P. Ratliff, J. Y. Suen, E. Hanna, T. P. Brent, and C.-Y. Fan
O6-Methylguanine-DNA Methyltransferase Gene: Epigenetic Silencing and Prognostic Value in Head and Neck Squamous Cell Carcinoma
Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 967 - 975.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. G. Herman and S. B. Baylin
Gene Silencing in Cancer in Association with Promoter Hypermethylation
N. Engl. J. Med., November 20, 2003; 349(21): 2042 - 2054.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Nagasaka, G. B. Sharp, K. Notohara, T. Kambara, H. Sasamoto, H. Isozaki, D. G. MacPhee, J. R. Jass, N. Tanaka, and N. Matsubara
Hypermethylation of O6-Methylguanine-DNA Methyltransferase Promoter May Predict Nonrecurrence after Chemotherapy in Colorectal Cancer Cases
Clin. Cancer Res., November 1, 2003; 9(14): 5306 - 5312.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. H. Kang, H. J. Lee, K. S. Hwang, S. Lee, J.-H. Kim, and J.-S. Kim
Aberrant CpG Island Hypermethylation of Chronic Gastritis, in Relation to Aging, Gender, Intestinal Metaplasia, and Chronic Inflammation
Am. J. Pathol., October 1, 2003; 163(4): 1551 - 1556.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Heighway, G.P. Margison, and M.F. Santibanez-Koref
The alleles of the DNA repair gene O6-alkylguanine-DNA alkyltransferase are expressed at different levels in normal human lung tissue
Carcinogenesis, October 1, 2003; 24(10): 1691 - 1694.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. C. Pulling, K. K. Divine, D. M. Klinge, F. D. Gilliland, T. Kang, A. G. Schwartz, T. J. Bocklage, and S. A. Belinsky
Promoter Hypermethylation of the O6-Methylguanine-DNA Methyltransferase Gene: More Common in Lung Adenocarcinomas from Never-Smokers than Smokers and Associated with Tumor Progression
Cancer Res., August 15, 2003; 63(16): 4842 - 4848.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-P. J. Issa
Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes
Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. V. Brock, M. Gou, Y. Akiyama, A. Muller, T.-T. Wu, E. Montgomery, M. Deasel, P. Germonpre, L. Rubinson, R. F. Heitmiller, et al.
Prognostic Importance of Promoter Hypermethylation of Multiple Genes in Esophageal Adenocarcinoma
Clin. Cancer Res., August 1, 2003; 9(8): 2912 - 2919.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. P. Margison, A. C. Povey, B. Kaina, and M. F. Santibanez Koref
Variability and regulation of O6-alkylguanine-DNA alkyltransferase
Carcinogenesis, April 1, 2003; 24(4): 625 - 635.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
O. Galm, H. Yoshikawa, M. Esteller, R. Osieka, and J. G. Herman
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma
Blood, April 1, 2003; 101(7): 2784 - 2788.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Kondo, L. Shen, and J.-P. J. Issa
Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer
Mol. Cell. Biol., January 1, 2003; 23(1): 206 - 215.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
J. Brabender, H. Usadel, R. Metzger, P. M. Schneider, J. Park, D. Salonga, D. D. Tsao-Wei, S. Groshen, R. V. Lord, N. Takebe, et al.
Quantitative O6-Methylguanine DNA Methyltransferase Methylation Analysis in Curatively Resected Non-Small Cell Lung Cancer: Associations with Clinical Outcome
Clin. Cancer Res., January 1, 2003; 9(1): 223 - 227.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Beatty, A. Terry, J. MacDonald, E. Gault, S. Cevario, S. J. O'Brien, E. Cameron, and J. C. Neil
Feline Immunodeficiency Virus Integration in B-Cell Lymphoma Identifies a Candidate Tumor Suppressor Gene on Human Chromosome 15q15
Cancer Res., December 15, 2002; 62(24): 7175 - 7180.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S A Pileri, E Sabattini, P Rosito, P L Zinzani, S Ascani, G Fraternali-Orcioni, B Gamberi, M Piccioli, D Vivenza, B Falini, et al.
Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics
J. Clin. Pathol., September 1, 2002; 55(9): 684 - 688.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. E. Dolan and R. L. Schilsky
Silence Is Golden: Gene Hypermethylation and Survival in Large-Cell Lymphoma
J Natl Cancer Inst, January 2, 2002; 94(1): 6 - 7.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.